TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02713698

Intervention type: DRUG
Intervention: Propofol
Description: The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL.

Intervention type: DRUG
Intervention: Propofol
Description: The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL.

Intervention type: DRUG
Intervention: Propofol
Description: The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL.
Study: NCT00730392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
Study: NCT03111849

Intervention type: OTHER
Intervention: sarcopenia
Description: Prevalence of sarcopenia in hospitalized chronic obstructive patients
Study: NCT01778452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy
Description: endometrial biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy
Description: endometrial biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial biopsy
Description: endometrial biopsy
Study: NCT00883740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
Study: NCT05399186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early preoperative assessment and optimization
Description: The interventional group received early preoperative assessment and optimization (6-12 months) prior to total joint arthroplastic surgery in cooperation between hospital and primary care
Study: NCT03284424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT01426828

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CD3/CD28
Description: CD3/CD28 activated autologous lymphocytes intravenously

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CD3/CD28
Description: CD3/CD28 activated autologous lymphocytes intravenously
Study: NCT03001869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HBED-CC-PSMA PET/CT
Description: 68Ga-HBED-CC-PSMA PET/CT Scan
Study: NCT00729703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ovatio DR 6550
Description: Dual-chamber ICD therapy with minimized ventricular pacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OVATIO DR 6550
Description: Single-chamber device therapy with settings which are common in clinical practice.
Study: NCT02357173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic cigarette
Study: NCT01253629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication identical in appearance to active medication was provided
Study: NCT01622647

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP)
Description: Subjects will receive NCPAP
Study: NCT02279875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Study: NCT02376426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29, 57.
Study: NCT02376426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29, 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29, 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29, 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29, 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29, 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29, 57.
Study: NCT02279875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)
Description: isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg
Study: NCT04499144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified buccal flap and subepithelial connective palatal flap
Description: The connective flap was harvested from the deeper area of the palatal mucosa. Pedicle flap dimensions were reported using the periodontal probe. The flap was then rotated to cover the oro antral communication (OAC) area. The rotation could be in mesial or distal direction, related to OAC position and for the convenience of the donor site. The connective palatal flap was sutured to the buccal periostium using mattress sutures.
Study: NCT04521062

Intervention type: DEVICE
Group type: OTHER
Intervention: Dilapan S
Description: Placement of Dilapan S
Study: NCT03877068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM - Continues Glucose Monitoring sensor system
Description: A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay up to 10 days using the Dexcom Studio software to download the Dexcom receiver data.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POC BG - Point-of-Care Blood Glucose monitoring
Description: Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay up to 10 days.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: POC BG - Point-of-Care Blood Glucose monitoring
Description: Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay up to 10 days.
Study: NCT04398004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Treatment with 500 mg Clarithromycin orally twice daily for seven days
Study: NCT03098719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Mobility
Description: see detailed discription
Study: NCT02162537

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 IV (with adequate hydration) on D1 every 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 IV (with adequate hydration) on D1 every 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed
Description: 500mg/m² IV(10 min. infusion, preceded by the usual folic acid, vitamin B12 and corticosteroid premedication)on D1 every 3 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed
Description: 500mg/m² IV(10 min. infusion, preceded by the usual folic acid, vitamin B12 and corticosteroid premedication)on D1 every 3 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 7.5 mg/kg on D1 every 3 weeks. In case of eligibility for Bevacizumab, the latter will not be started until C2.

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 7.5 mg/kg on D1 every 3 weeks. In case of eligibility for Bevacizumab, the latter will not be started until C2.

Intervention type: RADIATION
Group type: OTHER
Intervention: Cerebral Radiotherapy
Description: Cerebral radiotherapy (encephalon in toto, 30 gy 10 sessions and 12 days) immediately after randomization before D1.If the number of brain metastases is less than or equal to 5 and less than or equal to 5 cm size, cerebral stereotactic radiotherapy condition may be proposed. The recommended interval between randomisation and D1 will be approximately 4 weeks.

Intervention type: RADIATION
Group type: OTHER
Intervention: Cerebral Radiotherapy
Description: Cerebral radiotherapy (encephalon in toto, 30 gy 10 sessions and 12 days) immediately after randomization before D1.If the number of brain metastases is less than or equal to 5 and less than or equal to 5 cm size, cerebral stereotactic radiotherapy condition may be proposed. The recommended interval between randomisation and D1 will be approximately 4 weeks.
Study: NCT02835547

Intervention type: OTHER
Intervention: Data collection
Description: Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)

Intervention type: OTHER
Intervention: Data collection
Description: Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)

Intervention type: OTHER
Intervention: Data collection
Description: Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)

Intervention type: OTHER
Intervention: Data collection
Description: Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)

Intervention type: OTHER
Intervention: Data collection
Description: Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
Study: NCT02376426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29, 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
Study: NCT02471924

Intervention type: OTHER
Group type: OTHER
Intervention: Trans thoraciq cardiac ultrasonography
Description: Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
Study: NCT00614029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sumatriptan (via Intraject System)
Description: 0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sumatriptan (via Intraject System)
Description: 0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sumatriptan (via Intraject System)
Description: 0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
Study: NCT02357173

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cigarette group
Study: NCT00685048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 minutes of psycho-education
Description: Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 minutes of brief advice
Description: Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: four 50-minute individual therapy sessions of MET & CBT
Description: MET \& CBT
Study: NCT04465916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
Description: Oral tablets
Study: NCT01249690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib,Pirarubicin,Dexamethasone
Description: Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide,Pirarubicin,Dexamethasone
Description: Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
Study: NCT02228369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3759
Description: Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: AZD9291 160mg once daily
Study: NCT00155259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel , Cisplatin , Capecitabine
Study: NCT00712907

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin C (Mayrhofer) 24mg/min i.v. for 64 min
Description: Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 100% O2 (AGA) two times for 12 min
Description: Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 100% O2 (AGA) two times for 12 min
Description: Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997
Study: NCT01106118

Intervention type: DRUG
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician
Study: NCT00871065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: 20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
Study: NCT00306137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trasylol (Aprotinin, BAYA0128)
Description: Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.~Subjects will be stratified into one of the 4 following strata:~* Stratum 1: complete primary pneumonectomy~* Stratum II: decortication or completion pneumonectomy~* Stratum III: esophagectomy by transhiatal approach~* Stratum IV: esophagectomy by transthoracic approach

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
Study: NCT01293318

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00891501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cell implantation
Description: The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
Study: NCT01393626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets twice daily
Study: NCT00614029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sumatriptan (via Intraject System)
Description: 0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
Study: NCT01393626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: oral tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: oral tablets twice daily
Study: NCT00627458

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix Hexa
Description: Vaccine administered as a booster dose at 16-20 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix Hexa
Description: Vaccine administered as a booster dose at 16-20 months of age
Study: NCT00627458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix Hexa
Description: Vaccine administered as a booster dose at 16-20 months of age
Study: NCT03447054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined TDCS active and ICT active
Description: Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Combined TDCS sham and ICT active
Description: Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined TDCS active and ICT inactive
Description: Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Sham TDCS and inactive ICT
Description: Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days
Study: NCT01825616

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2 mushroom powder
Description: Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mushroom powder without vitamin D2